arsenic trioxide has been researched along with pyrazines in 47 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 27 (57.45) | 29.6817 |
| 2010's | 19 (40.43) | 24.3611 |
| 2020's | 1 (2.13) | 2.80 |
| Authors | Studies |
|---|---|
| Hussein, MA | 1 |
| Gisslinger, H; Kees, M | 1 |
| Chen, SL | 1 |
| Kaufman, J; Lonial, S | 1 |
| Cardinale, G; Gervasi, F; Pagnucco, G | 1 |
| Kaplow, R | 1 |
| Chng, WJ; Lau, LG; Mow, BM; Yusof, N | 1 |
| Saunders, G | 1 |
| Murakami, H | 1 |
| Anderson, KC; Hideshima, T; Richardson, PG; Schlossman, R | 1 |
| Hess, U | 1 |
| Hussein, MA; Kalmadi, SR | 1 |
| Berenson, JR; Mapes, R; Matous, J; Morrison, B; Swift, RA; Yeh, HS | 1 |
| Chen, GQ; Li, D; Liu, W; Wang, Y; Wang, YC; Wu, YL; Yan, H | 1 |
| Abou-Merhi, R; Arnoult, D; Bazarbachi, A; Dbouk, H; de Thé, H; El Hajj, H; El-Sabban, ME; Gessain, A; Hermine, O; Khoriaty, R; Mahieux, R; Munier, S | 1 |
| Baritaki, S; Berenson, JR; Bonavida, B; Campbell, RA; Chen, H; Gordon, M; Pang, S; Said, J; Sanchez, E; Shalitin, D; Steinberg, JA; Wang, C | 1 |
| Fu, YB; Li, L; Meng, FY; Sun, QX; Tian, S | 1 |
| Cai, YX; Fu, YB; Li, L; Meng, FY; Sun, QX | 2 |
| Fu, YB; Li, CY; Li, L; Meng, FY; Song, LL; Sun, QX; Yi, ZS | 1 |
| Takatoku, M | 1 |
| Fu, WJ; Hou, J; Wang, DX; Yuan, ZG; Zhou, LL | 1 |
| Fu, W; Hou, J; Jiang, H; Wang, D; Yuan, Z; Zhou, L | 1 |
| Berenson, JR; Yellin, O | 1 |
| He, Y; Hu, XX; Lü, SQ; Wang, JM; Yang, JM; Zhou, H | 1 |
| Dahdaleh, FS; Musallam, KM; Shamseddine, AI; Taher, AT | 1 |
| Brossart, P; Fröhlich, E; Wahl, R | 1 |
| Ballon, DJ; Chang, CC; Chen, H; Feng, Y; Huang, W; Kamble, RT; Liao, B; Preti, HA; Rice, L; Wen, J; Zu, Y | 1 |
| Canestraro, M; Cine, N; Galimberti, S; Guerrini, F; Metelli, MR; Nagy, B; Palumbo, GA; Petrini, M; Piaggi, S; Savli, H; Tibullo, D | 1 |
| Abeltino, M; Agnelli, L; Bolzoni, M; Bonomini, S; Colla, S; Giuliani, N; Neri, A; Rizzoli, V; Storti, P; Todoerti, K | 1 |
| Chen, XW; Xia, HL; Xia, RX | 2 |
| Bechelli, J; Ifthikharuddin, JJ; Jordan, CT; Liesveld, JL; Lu, C; Messina, P; Mulford, D; Phillips Ii, GL; Rosell, KE | 1 |
| Sun, ZQ; Tan, DW | 1 |
| Bashir, Q; Bassett, RL; Champlin, RE; Giralt, SA; Hosing, CM; Khan, H; Orlowski, RZ; Parmar, S; Popat, UR; Qazilbash, MH; Shah, JJ; Shah, N; Sharma, M; Thall, PF; Wang, M | 1 |
| Goel, A; Spitz, DR; Weiner, GJ | 1 |
| Batár, P; Kiss, A; Rejto, L; Reményi, G; Szász, R; Telek, B; Udvardy, M; Ujj, ZÁ | 1 |
| Guo, G; Hu, T; Shen, Y; Wang, C; Wu, Y; Xu, Y | 1 |
| Chen, Y; Ge, QF; Lu, Y; Mu, QT; Ouyang, GF; Zhang, Y | 1 |
| Chen, Z; Jung, HJ; McCarty, N | 1 |
| Hao, LM; Huang, JQ; Li, XM; Wang, SM; Wei, LY; Wu, HY | 1 |
| Chao, NJ; de Castro, CM; Diehl, LF; Gasparetto, C; Gockerman, JP; Held, LA; Horwitz, ME; Long, GD; Moore, JO; Rizzieri, D | 1 |
| Chan, SM; Feng, W; Huang, M; Li, MX; Majeti, R; Mitchell, BS; Thomas, D | 1 |
| Cui, JW; Elmahi, AY; Hao, SS; Li, D; Li, W; Niu, C; Wang, GJ | 1 |
| Aki, T; Funakoshi, T; Uemura, K; Unuma, K; Watanabe, M | 1 |
| Wei, W; Wu, C; Wu, Y; Xu, W; Yan, H; Ye, C; Yu, Q | 1 |
| Naoe, T | 1 |
17 review(s) available for arsenic trioxide and pyrazines
| Article | Year |
|---|---|
Nontraditional cytotoxic therapies for relapsed/refractory multiple myeloma.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Boronic Acids; Bortezomib; Cell Adhesion Molecules; Cytokines; Humans; Multiple Myeloma; Neovascularization, Pathologic; Oxides; Pyrazines; Thalidomide; Treatment Outcome | 2002 |
Therapy strategies for multiple myeloma: current status.
Topics: Adjuvants, Immunologic; Aged; Angiogenesis Inhibitors; Anti-Inflammatory Agents; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Bone Marrow Transplantation; Boronic Acids; Bortezomib; Clinical Trials as Topic; Clinical Trials, Phase II as Topic; Dexamethasone; Diphosphonates; Drug Therapy, Combination; Erythropoietin; Glucocorticoids; Growth Inhibitors; Humans; Immunosuppressive Agents; Middle Aged; Multiple Myeloma; Oxides; Peripheral Blood Stem Cell Transplantation; Protease Inhibitors; Pyrazines; Randomized Controlled Trials as Topic; Stem Cell Transplantation; Thalidomide; Time Factors; Transplantation, Autologous; Transplantation, Homologous | 2003 |
Multiple myeloma: the role of transplant and novel treatment strategies.
Topics: Adjuvants, Immunologic; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Boronic Acids; Bortezomib; Humans; Multiple Myeloma; Oxides; Pyrazines; Stem Cell Transplantation; Thalidomide; Transplantation, Homologous | 2004 |
Targeting multiple myeloma cells and their bone marrow microenvironment.
Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Bone Marrow Cells; Boronic Acids; Bortezomib; Cell Adhesion; Cytokines; Disease Progression; Disease-Free Survival; Humans; Ligands; Multiple Myeloma; Neovascularization, Pathologic; Oxides; Protease Inhibitors; Pyrazines; Signal Transduction; Thalidomide | 2004 |
Innovations in antineoplastic therapy.
Topics: Adjuvants, Immunologic; Alemtuzumab; Aminoglycosides; Anastrozole; Androstadienes; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Benzamides; Bile; Boronic Acids; Bortezomib; Capecitabine; Cetuximab; Decanoic Acids; Deoxycytidine; Docetaxel; Drug Approval; Estradiol; Fluorouracil; Fulvestrant; Gefitinib; Gemtuzumab; Humans; Imatinib Mesylate; Letrozole; Leuprolide; Nitriles; Oligopeptides; Organoplatinum Compounds; Oxaliplatin; Oxides; Piperazines; Polyesters; Pyrazines; Pyrimidines; Quinazolines; Taxoids; Thionucleotides; Tissue Extracts; Triazoles; United States; United States Food and Drug Administration; Vidarabine Phosphate | 2005 |
Targeted therapy in multiple myeloma.
Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Boronic Acids; Bortezomib; Clinical Trials as Topic; DNA, Antisense; Drug Delivery Systems; Farnesyltranstransferase; Humans; Immunosuppressive Agents; Lovastatin; Multiple Myeloma; Oxides; Protease Inhibitors; Pyrazines; Thalidomide | 2005 |
Overview of drug therapy for multiple myeloma.
Topics: Animals; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Boronic Acids; Bortezomib; Clinical Trials as Topic; Humans; Multiple Myeloma; Myeloma Proteins; Oxides; Pyrazines; Thalidomide | 2005 |
[New strategy for the treatment of multiple myeloma].
Topics: Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Boronic Acids; Bortezomib; Dexamethasone; Drug Design; Drug Therapy, Combination; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Multiple Myeloma; Oxides; Prognosis; Protease Inhibitors; Purines; Pyrazines; Roscovitine; Thalidomide; Transplantation Conditioning | 2005 |
New treatments for multiple myeloma.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Boronic Acids; Bortezomib; Clinical Trials as Topic; Dexamethasone; Humans; Lenalidomide; Melphalan; Multiple Myeloma; Oxides; Pyrazines; Thalidomide | 2005 |
[The plasma cell myeloma--molecular pathogenesis and target therapies].
Topics: Aged; Angiogenesis Inhibitors; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Boronic Acids; Bortezomib; Cell Communication; Chromosome Aberrations; Gene Expression; Glycoproteins; Growth Inhibitors; Humans; Immunologic Factors; Immunosuppressive Agents; Lenalidomide; Multiple Myeloma; Osteoporosis; Osteoprotegerin; Oxides; Protease Inhibitors; Pyrazines; Randomized Controlled Trials as Topic; Receptors, Cytoplasmic and Nuclear; Receptors, Tumor Necrosis Factor; Thalidomide; Time Factors | 2006 |
The emerging role of arsenic trioxide as an immunomodulatory agent in the management of multiple myeloma.
Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Boronic Acids; Bortezomib; Clinical Trials as Topic; Drug Resistance, Neoplasm; History, 18th Century; History, 20th Century; History, 21st Century; History, Ancient; Humans; Immunologic Factors; Lenalidomide; Multiple Myeloma; Oxides; Pyrazines; Thalidomide | 2006 |
[Molecular targeting therapy for multiple myeloma].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Bevacizumab; Boronic Acids; Bortezomib; Clinical Trials as Topic; Drug Therapy, Combination; Enzyme Inhibitors; Farnesyltranstransferase; Histone Deacetylase Inhibitors; Humans; Immunosuppressive Agents; Lenalidomide; Multiple Myeloma; Oxides; Protease Inhibitors; Pyrazines; Thalidomide; TNF-Related Apoptosis-Inducing Ligand; Vascular Endothelial Growth Factor A | 2007 |
New drugs in multiple myeloma.
Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Boronic Acids; Bortezomib; Clinical Trials as Topic; Humans; Lenalidomide; Multiple Myeloma; Oxides; Pyrazines; Thalidomide | 2008 |
Incidence and prophylaxis of venous thromboembolic events in multiple myeloma patients receiving immunomodulatory therapy.
Topics: Arsenic Trioxide; Arsenicals; Aspirin; Boronic Acids; Bortezomib; Heparin, Low-Molecular-Weight; Humans; Incidence; Lenalidomide; Multiple Myeloma; Oxides; Pyrazines; Thalidomide; Venous Thromboembolism | 2009 |
Manipulation of cellular redox parameters for improving therapeutic responses in B-cell lymphoma and multiple myeloma.
Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Boronic Acids; Bortezomib; Combined Modality Therapy; Dexamethasone; Drug Resistance, Neoplasm; Humans; Lymphoma, B-Cell; Multiple Myeloma; Oxidation-Reduction; Oxidative Stress; Oxides; Pyrazines; Radiotherapy | 2012 |
[Current treatment of acute myeloid leukaemia in adults].
Topics: Age Factors; Aminoglycosides; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Boronic Acids; Bortezomib; Cytarabine; Disease-Free Survival; Drug Resistance, Neoplasm; fms-Like Tyrosine Kinase 3; Gemtuzumab; Hematopoietic Stem Cell Transplantation; Humans; Idarubicin; Leukemia, Myeloid, Acute; Mitoxantrone; Molecular Targeted Therapy; Oxides; Prognosis; Pyrazines; Recurrence; Transplantation, Homologous; Treatment Outcome; Tretinoin | 2012 |
＜Editors' Choice＞ How to improve outcomes of elderly patients with acute myeloid leukemia: era of excitement.
Topics: Aged; Aged, 80 and over; Aminopyridines; Aniline Compounds; Antineoplastic Agents; Arsenic Trioxide; Azacitidine; Benzimidazoles; Bridged Bicyclo Compounds, Heterocyclic; Decitabine; fms-Like Tyrosine Kinase 3; Humans; Isocitrate Dehydrogenase; Leukemia, Myeloid, Acute; Molecular Targeted Therapy; Phenylurea Compounds; Precision Medicine; Proto-Oncogene Proteins c-bcl-2; Pyrazines; Smoothened Receptor; Staurosporine; Sulfonamides; Survival Rate; Tretinoin; Triazines | 2020 |
4 trial(s) available for arsenic trioxide and pyrazines
| Article | Year |
|---|---|
A phase I/II study of arsenic trioxide/bortezomib/ascorbic acid combination therapy for the treatment of relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Ascorbic Acid; Boronic Acids; Bortezomib; Disease-Free Survival; Female; Humans; Male; Middle Aged; Multiple Myeloma; Oxides; Pyrazines; Recurrence; Survival Analysis; Treatment Failure; Treatment Outcome | 2007 |
Proteasome inhibition in myelodysplastic syndromes and acute myelogenous leukemia cell lines.
Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Azacitidine; Benzenesulfonates; Boronic Acids; Bortezomib; Cell Line, Tumor; Cell Proliferation; Cytarabine; Cytokines; Farnesyltranstransferase; Hematopoietic Stem Cells; Humans; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Niacinamide; Oxides; Phenylurea Compounds; Protease Inhibitors; Proteasome Inhibitors; Pyrazines; Pyridines; Sorafenib | 2011 |
A randomized phase 2 trial of a preparative regimen of bortezomib, high-dose melphalan, arsenic trioxide, and ascorbic acid.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Ascorbic Acid; Blood Transfusion, Autologous; Boronic Acids; Bortezomib; Disease-Free Survival; Drug Administration Schedule; Female; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Humans; Male; Melphalan; Middle Aged; Multiple Myeloma; Oxides; Prognosis; Pyrazines; Transplantation Conditioning | 2012 |
A Phase I study of arsenic trioxide (Trisenox), ascorbic acid, and bortezomib (Velcade) combination therapy in patients with relapsed/refractory multiple myeloma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Ascorbic Acid; Boronic Acids; Bortezomib; Female; Humans; Male; Middle Aged; Multiple Myeloma; Oxides; Pyrazines; Recurrence | 2013 |
26 other study(ies) available for arsenic trioxide and pyrazines
| Article | Year |
|---|---|
[Targeted in therapies multiple myeloma].
Topics: Arsenic Trioxide; Arsenicals; Boronic Acids; Bortezomib; Drug Therapy, Combination; Humans; Multiple Myeloma; Oxides; Pyrazines; Thalidomide | 2004 |
Arsenic trioxide and proteasome inhibitor bortezomib synergistically induce apoptosis in leukemic cells: the role of protein kinase Cdelta.
Topics: Adult; Apoptosis; Arsenic Trioxide; Arsenicals; Boronic Acids; Bortezomib; Cell Line, Tumor; Drug Synergism; Enzyme Activation; Humans; Leukemia; Middle Aged; Mitogen-Activated Protein Kinases; Oxides; Protease Inhibitors; Protein Kinase C-delta; Pyrazines; Tumor Cells, Cultured | 2007 |
PS-341 or a combination of arsenic trioxide and interferon-alpha inhibit growth and induce caspase-dependent apoptosis in KSHV/HHV-8-infected primary effusion lymphoma cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Arsenic Trioxide; Arsenicals; bcl-X Protein; Boronic Acids; Bortezomib; Caspases; Cell Proliferation; Herpesvirus 8, Human; Humans; Interferon-alpha; Lymphoma; Membrane Potential, Mitochondrial; NF-kappa B; Oxides; Protease Inhibitors; Pyrazines | 2007 |
Antimyeloma effects of arsenic trioxide are enhanced by melphalan, bortezomib and ascorbic acid.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Antioxidants; Apoptosis; Arsenic Trioxide; Arsenicals; Ascorbic Acid; Boronic Acids; Bortezomib; Cell Line, Tumor; Cell Proliferation; Drug Synergism; Enzyme-Linked Immunosorbent Assay; Humans; Immunoglobulin G; Melphalan; Mice; Mice, SCID; Multiple Myeloma; Oxides; Pyrazines; Xenograft Model Antitumor Assays | 2007 |
[HL-60 cell apoptosis induced by bortezomib alone or in combination with arsenic trioxide in vitro].
Topics: Animals; Apoptosis; Arsenic Trioxide; Arsenicals; Boronic Acids; Bortezomib; Cell Proliferation; Cell Survival; Dose-Response Relationship, Drug; Drug Synergism; Electrophoresis; Flow Cytometry; HL-60 Cells; Humans; Oxides; Pyrazines; Time Factors | 2007 |
[Effect of bortezomib used alone or in combination with arsenic trioxide on HL-60 cell xenograft in nude mice].
Topics: Animals; Apoptosis; Arsenic Trioxide; Arsenicals; Boronic Acids; Bortezomib; Cell Proliferation; Disease Models, Animal; HL-60 Cells; Humans; Leukemia; Male; Mice; Mice, Nude; Oxides; Pyrazines; Random Allocation; Xenograft Model Antitumor Assays | 2007 |
[STI571 enhances the effect of arsenic trioxide and Velcade on bcr/abl+-CD34+ cell proliferation and apoptosis].
Topics: Adult; Aged; Apoptosis; Arsenic Trioxide; Arsenicals; Benzamides; Boronic Acids; Bortezomib; Cell Proliferation; Drug Synergism; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Middle Aged; Oxides; Piperazines; Pyrazines; Pyrimidines; Tumor Cells, Cultured | 2007 |
[Effect of arsenic trioxide combined with bortezomib on proliferation, apoptosis and beta-catenin level in myeloma cell lines].
Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; beta Catenin; Boronic Acids; Bortezomib; Cell Proliferation; Drug Synergism; Humans; Multiple Myeloma; Oxides; Pyrazines; Tumor Cells, Cultured | 2008 |
Arsenic trioxide and 2-methoxyestradiol reduce beta-catenin accumulation after proteasome inhibition and enhance the sensitivity of myeloma cells to Bortezomib.
Topics: 2-Methoxyestradiol; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Arsenic Trioxide; Arsenicals; beta Catenin; Blotting, Western; Boronic Acids; Bortezomib; Cell Proliferation; Drug Therapy, Combination; Enzyme-Linked Immunosorbent Assay; Estradiol; Gene Expression Regulation, Neoplastic; Humans; Multiple Myeloma; Oxides; Proteasome Inhibitors; Pyrazines; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; RNA, Small Interfering; Tumor Cells, Cultured | 2008 |
[Synergistic effects of arsenic trioxide and proteasome inhibitor bortezomib on apoptosis induction in Raji cell line].
Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Boronic Acids; Bortezomib; Burkitt Lymphoma; Cell Line, Tumor; Drug Synergism; Humans; Oxides; Protease Inhibitors; Pyrazines | 2008 |
Induction of iodide uptake in transformed thyrocytes: a compound screening in cell lines.
Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Boronic Acids; Bortezomib; Carcinoma; Cell Differentiation; Cell Line, Tumor; Cell Proliferation; Drug Screening Assays, Antitumor; Humans; Iodides; Lovastatin; Neoplasm Metastasis; Oxides; Pyrazines; Sirolimus; Thymus Gland; Thyroid Neoplasms; Tretinoin | 2009 |
[In vitro effect of bortezomib alone or in combination with harringtonine or arsenic trioxide on proliferation and apoptosis of multidrug resistant leukemia cells].
Topics: Adolescent; Adult; Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Boronic Acids; Bortezomib; Cell Line, Tumor; Cell Proliferation; Child; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Female; Harringtonines; HL-60 Cells; Humans; Male; Oxides; Pyrazines; Young Adult | 2008 |
Enhanced antimyeloma cytotoxicity by the combination of arsenic trioxide and bortezomib is further potentiated by p38 MAPK inhibition.
Topics: Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Boronic Acids; Bortezomib; Drug Synergism; Enzyme Activation; HSP27 Heat-Shock Proteins; Humans; Multiple Myeloma; Oxides; p38 Mitogen-Activated Protein Kinases; Pyrazines; STAT3 Transcription Factor | 2010 |
Synergistic antiproliferative effect of arsenic trioxide combined with bortezomib in HL60 cell line and primary blasts from patients affected by myeloproliferative disorders.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Arsenic Trioxide; Arsenicals; Biomarkers, Tumor; Blast Crisis; Blotting, Western; Boronic Acids; Bortezomib; Caspase 8; Cell Cycle; Cell Proliferation; Drug Synergism; Gene Expression Profiling; HL-60 Cells; Humans; Leukemia, Myeloid, Acute; Myeloproliferative Disorders; NF-kappa B; Oligonucleotide Array Sequence Analysis; Oxides; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-bcl-2; Pyrazines; Reactive Oxygen Species; Receptors, TNF-Related Apoptosis-Inducing Ligand; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; TNF-Related Apoptosis-Inducing Ligand | 2010 |
The proapoptotic effect of zoledronic acid is independent of either the bone microenvironment or the intrinsic resistance to bortezomib of myeloma cells and is enhanced by the combination with arsenic trioxide.
Topics: Aged; Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Boronic Acids; Bortezomib; Cell Proliferation; Diphosphonates; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Drug Synergism; Humans; Imidazoles; Middle Aged; Multiple Myeloma; Oxides; Polymerase Chain Reaction; Pyrazines; Zoledronic Acid | 2011 |
[NB4 cell apoptosis induced by bortezomib combined with As(2)O(3) and its mechanism].
Topics: Apoptosis; Arsenic Trioxide; Arsenicals; Boronic Acids; Bortezomib; Caspase 3; Caspase 9; Cell Line, Tumor; Humans; Oxides; Proto-Oncogene Proteins c-bcl-2; Pyrazines; RNA, Small Interfering; Transfection | 2011 |
[Mechanism of apoptosis induced by bortezomib and As2O3 in APL cell line NB4].
Topics: Apoptosis; Arsenic Trioxide; Arsenicals; Boronic Acids; Bortezomib; Cell Line, Tumor; Humans; Leukemia, Promyelocytic, Acute; Oxides; Pyrazines | 2011 |
[Effects of bortezomib alone or combined with arsenic trioxide on the apoptosis of Jurkat cells and expression of livin mRNA].
Topics: Adaptor Proteins, Signal Transducing; Apoptosis; Arsenic Trioxide; Arsenicals; Boronic Acids; Bortezomib; Humans; Inhibitor of Apoptosis Proteins; Jurkat Cells; Neoplasm Proteins; Oxides; Pyrazines; RNA, Messenger | 2011 |
Tetramethylpyrazine potentiates arsenic trioxide activity against HL-60 cell lines.
Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Blotting, Western; Cell Cycle; Cell Differentiation; Cell Proliferation; Drug Synergism; Flow Cytometry; HL-60 Cells; Humans; Oxides; Pyrazines; Reverse Transcriptase Polymerase Chain Reaction | 2012 |
Effects of arsenic trioxide combined with bortezomib on apoptosis of multiple myeloma cell line KM3 and its mechanisms.
Topics: Apoptosis; Apoptosis Regulatory Proteins; Arsenic Trioxide; Arsenicals; Bcl-2-Like Protein 11; bcl-X Protein; Boronic Acids; Bortezomib; Caspase 3; Cell Line, Tumor; Humans; Membrane Proteins; Multiple Myeloma; Oxides; Proto-Oncogene Proteins; Pyrazines | 2012 |
Synergistic anticancer effects of arsenic trioxide with bortezomib in mantle cell lymphoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Arsenic Trioxide; Arsenicals; Boronic Acids; Bortezomib; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cyclin D1; Drug Synergism; Humans; Lymphoma, Mantle-Cell; Oxides; Pyrazines | 2012 |
[Effects of arsenic trioxide combined with bortezomib on proliferation and apoptosis of K562 cells and their mechanism].
Topics: Apoptosis; Arsenic Trioxide; Arsenicals; Boronic Acids; Bortezomib; Cell Proliferation; Drug Synergism; Humans; K562 Cells; NF-kappa B; Oxides; Pyrazines | 2012 |
Role of cysteine 288 in nucleophosmin cytoplasmic mutations: sensitization to toxicity induced by arsenic trioxide and bortezomib.
Topics: Acetylcysteine; Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Boronic Acids; Bortezomib; Cell Nucleolus; Cell Proliferation; Cysteine; Cytosol; Drug Resistance, Neoplasm; Flow Cytometry; Free Radical Scavengers; Humans; Leukemia, Myeloid, Acute; Mutation; Nuclear Proteins; Nucleophosmin; Oxides; Pyrazines; Reactive Oxygen Species; Tryptophan; Tumor Cells, Cultured | 2013 |
Effects of arsenic trioxide alone and in combination with bortezomib in multiple myeloma RPMI 8266 cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Arsenic Trioxide; Arsenicals; Boronic Acids; Bortezomib; Caspases; Cell Line, Tumor; Cell Proliferation; Cell Survival; G2 Phase Cell Cycle Checkpoints; Humans; Multiple Myeloma; Oxides; Proto-Oncogene Proteins c-bcl-2; Pyrazines | 2013 |
Activation of the ubiquitin-proteasome system against arsenic trioxide cardiotoxicity involves ubiquitin ligase Parkin for mitochondrial homeostasis.
Topics: Animals; Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Autophagy; Blotting, Western; Boronic Acids; Bortezomib; Heart Diseases; Homeostasis; Immunoprecipitation; Lysosomes; Membrane Potential, Mitochondrial; Mice; Microscopy, Fluorescence; Mitochondria, Heart; Myocytes, Cardiac; Oxides; Proteasome Endopeptidase Complex; Pyrazines; Ubiquitin; Ubiquitin-Protein Ligases; Voltage-Dependent Anion Channel 1 | 2014 |
Arsenic trioxide and bortezomib interact synergistically to induce apoptosis in chronic myelogenous leukemia cells resistant to imatinib mesylate through Bcr/Abl‑dependent mechanisms.
Topics: Apoptosis; Arsenic Trioxide; Arsenicals; Benzamides; Boronic Acids; Bortezomib; Caspase 3; Cell Line, Tumor; Down-Regulation; Drug Resistance, Neoplasm; Drug Synergism; Fusion Proteins, bcr-abl; Gene Expression Regulation, Leukemic; Humans; Imatinib Mesylate; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Oxides; Piperazines; Poly(ADP-ribose) Polymerases; Pyrazines; Pyrimidines; Reactive Oxygen Species; RNA, Messenger | 2014 |